113 related articles for article (PubMed ID: 8917366)
21. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
Bortoletto N; Scotet E; Myamoto Y; D'Oro U; Lanzavecchia A
Eur J Immunol; 2002 Nov; 32(11):3102-7. PubMed ID: 12385030
[TBL] [Abstract][Full Text] [Related]
22. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
23. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
24. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
[TBL] [Abstract][Full Text] [Related]
25. Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.
Simmons A; Whitehead RP; Kolokoltsov AA; Davey RA
Virol J; 2006 Feb; 3():8. PubMed ID: 16507098
[TBL] [Abstract][Full Text] [Related]
26. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
27. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
28. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
29. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
Blanco B; Holliger P; Alvarez-Vallina L
Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
[TBL] [Abstract][Full Text] [Related]
30. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
31. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells.
Sasaki T; Ikeda H; Sato M; Ohkuri T; Abe H; Kuroki M; Onodera M; Miyamoto M; Kondo S; Nishimura T
Cancer Sci; 2006 Sep; 97(9):920-7. PubMed ID: 16856879
[TBL] [Abstract][Full Text] [Related]
33. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy.
Clarke P; Mann J; Simpson JF; Rickard-Dickson K; Primus FJ
Cancer Res; 1998 Apr; 58(7):1469-77. PubMed ID: 9537250
[TBL] [Abstract][Full Text] [Related]
34. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
[TBL] [Abstract][Full Text] [Related]
35. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
36. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
Lehmann S; Perera R; Grimm HP; Sam J; Colombetti S; Fauti T; Fahrni L; Schaller T; Freimoser-Grundschober A; Zielonka J; Stoma S; Rudin M; Klein C; Umana P; Gerdes C; Bacac M
Clin Cancer Res; 2016 Sep; 22(17):4417-27. PubMed ID: 27117182
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
38. T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors.
Patel SD; Moskalenko M; Tian T; Smith D; McGuinness R; Chen L; Winslow GA; Kashmiri S; Schlom J; Stanners CP; Finer MH; McArthur JG
Cancer Gene Ther; 2000 Aug; 7(8):1127-34. PubMed ID: 10975673
[TBL] [Abstract][Full Text] [Related]
39. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Sep; 7(18):1527-35. PubMed ID: 11021590
[TBL] [Abstract][Full Text] [Related]
40. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]